1
|
Moutel M, Noel V, Jary A, Le Q, Lier C, Viguier M, Lebbe C, Azzouz B, Bani‐Sadr F. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data. Am J Hematol 2022; 97:E31-E34. [PMID: 34724250 DOI: 10.1002/ajh.26398] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 10/29/2021] [Accepted: 10/29/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Marin Moutel
- Department of Internal Medicine, Infectious Diseases, and Clinical Immunology Reims University Hospital Reims France
| | - Violaine Noel
- Department of Internal Medicine, Infectious Diseases, and Clinical Immunology Reims University Hospital Reims France
| | - Aude Jary
- Department of Virology, Hôpital Pitié Salpêtrière Assistance Publique des Hôpitaux de Paris Paris France
| | - Quoc‐Hung Le
- Department of Hematology Reims University Hospital Reims France
| | - Clément Lier
- Department of Virology Reims University Hospital Reims France
| | - Manuelle Viguier
- Department of Dermatology Reims University Hospital Reims France
| | - Céleste Lebbe
- Department of Dermatology, Hôpital Saint Louis Assistance Publique des Hôpitaux de Paris Paris France
| | - Brahim Azzouz
- Regional Centre for Pharmacovigilance and Pharmacoepidemiology Reims University Hospital Reims France
| | - Firouzé Bani‐Sadr
- Department of Internal Medicine, Infectious Diseases, and Clinical Immunology Reims University Hospital Reims France
- University of Reims Champagne‐Ardenne Reims France
| |
Collapse
|
2
|
Beauruelle C, Treluyer L, Pastuszka A, Cochard T, Lier C, Mereghetti L, Glaser P, Poyart C, Lanotte P. CRISPR Typing Increases the Discriminatory Power of Streptococcus agalactiae Typing Methods. Front Microbiol 2021; 12:675597. [PMID: 34349737 PMCID: PMC8328194 DOI: 10.3389/fmicb.2021.675597] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 06/15/2021] [Indexed: 11/25/2022] Open
Abstract
We explored the relevance of a Clustered regularly interspaced short palindromic repeats (CRISPR)-based genotyping tool for Streptococcus agalactiae typing and we compared this method to current molecular methods [multi locus sequence typing (MLST) and capsular typing]. To this effect, we developed two CRISPR marker schemes (using 94 or 25 markers, respectively). Among the 255 S. agalactiae isolates tested, 229 CRISPR profiles were obtained. The 94 and 25 markers made it possible to efficiently separate isolates with a high diversity index (0.9947 and 0.9267, respectively), highlighting a high discriminatory power, superior to that of both capsular typing and MLST (diversity index of 0.9017 for MLST). This method has the advantage of being correlated with MLST [through analysis of the terminal direct repeat (TDR) and ancestral spacers] and to possess a high discriminatory power (through analysis of the leader-end spacers recently acquired, which are the witnesses of genetic mobile elements encountered by the bacteria). Furthermore, this “one-shot” approach presents the benefit of much-reduced time and cost in comparison with MLST. On the basis of these data, we propose that this method could become a reference method for group B Streptococcus (GBS) typing.
Collapse
Affiliation(s)
- Clémence Beauruelle
- Département de Bactériologie-Virologie, Hygiène Hospitalière et Parasitologie-Mycologie, Centre Hospitalier Régional Universitaire (CHRU) de Brest, Brest, France.,Inserm, EFS, UMR 1078, GGB, Universitè de Bretagne Occidentale, Brest, France
| | - Ludovic Treluyer
- Institut Cochin, Team Bacteria and Perinatality, INSERM U1016, Paris, France
| | - Adeline Pastuszka
- INRAE, ISP, Université de Tours, Tours, France.,Service de Bactériologie-Virologie, CHRU de Tours, Tours, France
| | | | - Clément Lier
- INRAE, ISP, Université de Tours, Tours, France.,Service de Bactériologie-Virologie, CHRU de Tours, Tours, France
| | - Laurent Mereghetti
- INRAE, ISP, Université de Tours, Tours, France.,Service de Bactériologie-Virologie, CHRU de Tours, Tours, France
| | - Philippe Glaser
- Evolution and Ecology of Resistance to Antibiotics (EERA) Unit, Institut Pasteur, Paris, France.,UMR CNRS 3525, Paris, France
| | - Claire Poyart
- Institut Cochin, Team Bacteria and Perinatality, INSERM U1016, Paris, France.,CNRS UMR 8104, Paris Descartes University, Paris, France.,Department of Bacteriology, University Hospitals Paris Centre-Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | |
Collapse
|
3
|
Marlet J, Lier C, Roch E, Moreau A, Combe B, Handala L, Lefeuvre S, Maugey M, Elkrief L, d'Alteroche L, Potier P, Brand D, Gaudy-Graffin C. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. Antiviral Res 2021; 192:105106. [PMID: 34214504 DOI: 10.1016/j.antiviral.2021.105106] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 04/29/2021] [Accepted: 05/31/2021] [Indexed: 12/20/2022]
Abstract
Entecavir treatment failure can be observed in compliant patients despite an absence of detectable resistance mutations by Pol/RT Sanger sequencing. We hypothesized that these unexplained treatment failures could rely on other mechanisms of viral resistance, especially on mutations selected outside of the Pol/RT domain. Partial virological response to entecavir was observed in three patients treated with immunosuppressive drugs, without selection of Pol/RT resistance mutations. Mutations selected in the whole HBV genome during entecavir treatment and potentially associated with resistance were searched for using deep sequencing and characterized using a phenotypic resistance assay. Mutations Q206K (pre-core/core), Q120K (pre-S1/pre-S2, T-cell epitope) and A300E (spacer domain) were selected during entecavir treatment in patient #1 but were not associated with an increased level of resistance to entecavir or an increase in HBV replication capacity. Core promoter mutations T1753G, A1762T and G1764A were present as major mutations before and after treatment in patient #1. HBs Ag immune escape mutations were present as major mutations before and after treatment in patients #2 (sK122R, sT126I, sP127S and sG145R) and #3 (sM133I). We demonstrated that PVR to entecavir does not require selection of any resistance mutation in the whole HBV genome. Our results demonstrate that major mutations can be selected outside of the Pol/RT domain before or during entecavir treatment. These mutations could contribute to entecavir treatment failure by other mechanisms than an increased level of resistance.
Collapse
Affiliation(s)
- Julien Marlet
- INSERM U1259, Université de Tours et CHRU de Tours, France; Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, France.
| | - Clément Lier
- INSERM U1259, Université de Tours et CHRU de Tours, France; Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, France
| | | | - Alain Moreau
- INSERM U1259, Université de Tours et CHRU de Tours, France
| | - Benjamin Combe
- INSERM U1259, Université de Tours et CHRU de Tours, France
| | - Lynda Handala
- INSERM U1259, Université de Tours et CHRU de Tours, France
| | | | - Morgan Maugey
- INSERM U1259, Université de Tours et CHRU de Tours, France
| | - Laure Elkrief
- Service D'Hépato-gastroentérologie, CHRU de Tours, France
| | | | - Pascal Potier
- Service D'Hépato-gastroentérologie, CHR D'Orléans, France
| | - Denys Brand
- INSERM U1259, Université de Tours et CHRU de Tours, France; Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, France
| | - Catherine Gaudy-Graffin
- INSERM U1259, Université de Tours et CHRU de Tours, France; Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, France
| |
Collapse
|
4
|
Verduyn M, Botto G, Jaubert J, Lier C, Flament T, Guilleminault L. Serum IgG Concentrations in Adult Patients Experiencing Virus-Induced Severe Asthma Exacerbations. J Allergy Clin Immunol Pract 2019; 7:1507-1513.e1. [PMID: 30654200 PMCID: PMC7104119 DOI: 10.1016/j.jaip.2018.12.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 12/26/2018] [Accepted: 12/28/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND Patients experiencing severe asthma exacerbations have a poorer quality of life and an increase in morbidity and mortality. Viruses are frequently involved in asthma exacerbations. OBJECTIVE To determine the value of measuring serum IgG concentrations in asthma exacerbations and assess their link with viral infections in patients hospitalized for asthma. METHODS Patients hospitalized for asthma exacerbation were included in an observational study from January 1, 2015, to December 31, 2015. Serum IgG concentrations on admission were compared between patients with a positive upper airway viral sample and those with a negative viral sample. RESULTS Among the 82 patients included, those with positive viral nasopharyngeal samples (n = 40) presented with lower serum IgG concentrations during exacerbation than those with a negative viral sample (n = 42) (10.1 ± 2.3 g/L vs 11.5 ± 3.6 g/L; P < .05). The median concentration of serum IgG was lower in patients hospitalized for more than 3 days compared with those hospitalized for less than 3 days (10.0 g/L [8.2-12.4] vs 11.4 g/L [10.1-12.8]; P < .05) and in patients who received oral corticosteroid therapy for more than 5 days compared with those treated with oral steroids for less than 5 days (10.1 g/L [8.3-12.2] vs 11.6 g/L [10.0-13.8]; P < .05). CONCLUSIONS Serum IgG level was significantly lower when asthma exacerbations were associated with positive viral samples. The patients with lower serum IgG concentrations required longer hospitalizations and longer courses of steroids.
Collapse
Affiliation(s)
- Morgane Verduyn
- Department of Respiratory Medicine, University Hospital Centre of Réunion, Saint-Pierre, France
| | - Guillaume Botto
- Department of Respiratory Medicine, University Hospital Centre of Tours, Tours, France
| | - Julien Jaubert
- Department of Microbiology, University Hospital Centre of Réunion, Saint-Pierre, France
| | - Clément Lier
- Department of Virology, University Hospital Centre of Tours, Tours, France
| | - Thomas Flament
- Department of Respiratory Medicine, University Hospital Centre of Tours, Tours, France
| | - Laurent Guilleminault
- Department of Respiratory Medicine, University Hospital Centre of Toulouse, Toulouse, France; Center for Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR 5282, Toulouse III University, Toulouse, France.
| |
Collapse
|
5
|
Botto G, Verduyn M, Jaubert J, Lier C, Diot P, Marchand-Adam S, Guilleminault L. Exacerbation d’asthme et virus : quelles différences en fonction des zones climatiques ? Rev Mal Respir 2017. [PMCID: PMC7135053 DOI: 10.1016/j.rmr.2016.10.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Introduction Les exacerbations d’asthme correspondent à des aggravations rapides des symptômes respiratoires et sont responsables d’une morbidité et mortalité importantes. Les infections virales figurent parmi les causes les plus fréquentes des exacerbations mais les données épidémiologiques sont, dans leur grande majorité, issues de cohorte de pays tempérés. Peu de données sont disponibles dans les pays tropicaux malgré une augmentation de la prévalence de l’asthme dans ces régions ces dernières années. Méthodes Dans cette étude observationnelle réalisée sur l’année 2015, l’épidémiologie virale de patients adultes hospitalisés pour exacerbation d’asthme a été comparée entre la ville de Saint Pierre à la Réunion (climat tropical) et de Tours (climat tempéré). Un portage viral était recherché à l’entrée à l’hôpital par polymerase chain reaction (PCR) multiplex sur aspiration nasopharyngée. Seize virus ont été analysés : VRS A et B, rhinovirus, métapneumovirus, myxovirus influenzae A, H1N1, H5N1, parainfluenzae de 1 à 4, coronavirus 229E, NL63 et OC43, adénovirus, entérovirus. À la Réunion, le panel de virus recherché comprenait en plus coronavirus HKU1, bocavirus et paréchovirus. Résultats Au total, 100 patients ont été inclus dont 62 à Saint Pierre et 38 à Tours. La présence d’au moins un virus est retrouvé dans les aspirations naso-pharyngées chez 53 % des patients à Tours et 31 % des patients à Saint Pierre (p < 0,05). La répartition des virus diffère selon la géolocalisation. Le rhinovirus est l’espèce la plus fréquemment retrouvée dans les 2 groupes : soit 42 % des prélèvements à Saint Pierre et 30 % à Tours. On trouve de façon équivalente, entre les groupes, le virus influenza A dans 19 % des cas. Le classement diverge ensuite, l’entérovirus qui représente 19 % des aspirations naso-pharyngées à Tours n’est pas retrouvé à Saint Pierre. Inversement, le virus influenza H1N1 et le virus para-influenza identifiés dans 12 et 4 % des prélèvements à Saint Pierre sont absents à Tours. Les exacerbations semblent avoir une saisonnalité à Tours avec un pic en septembre et en hiver. Aucune saisonnalité n’est retrouvée sous le climat tropical de la Réunion. Conclusion La proportion de patients hospitalisés pour exacerbation d’asthme et ayant un prélèvement viral positif est plus faible en climat tropical qu’en climat tempéré. L’origine de ces exacerbations reste donc à déterminer. Il est nécessaire d’étudier spécifiquement en zone tropicale d’autres facteurs environnementaux comme les allergènes (moisissures…) ou les parasites.
Collapse
|
6
|
Lier C, Baticle E, Horvath P, Haguenoer E, Valentin AS, Glaser P, Mereghetti L, Lanotte P. Analysis of the type II-A CRISPR-Cas system of Streptococcus agalactiae reveals distinctive features according to genetic lineages. Front Genet 2015; 6:214. [PMID: 26124774 PMCID: PMC4466440 DOI: 10.3389/fgene.2015.00214] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 06/01/2015] [Indexed: 12/12/2022] Open
Abstract
CRISPR-Cas systems (clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins) are found in 90% of archaea and about 40% of bacteria. In this original system, CRISPR arrays comprise short, almost unique sequences called spacers that are interspersed with conserved palindromic repeats. These systems play a role in adaptive immunity and participate to fight non-self DNA such as integrative and conjugative elements, plasmids, and phages. In Streptococcus agalactiae, a bacterium implicated in colonization and infections in humans since the 1960s, two CRISPR-Cas systems have been described. A type II-A system, characterized by proteins Cas9, Cas1, Cas2, and Csn2, is ubiquitous, and a type I–C system, with the Cas8c signature protein, is present in about 20% of the isolates. Unlike type I–C, which appears to be non-functional, type II-A appears fully functional. Here we studied type II-A CRISPR-cas loci from 126 human isolates of S. agalactiae belonging to different clonal complexes that represent the diversity of the species and that have been implicated in colonization or infection. The CRISPR-cas locus was analyzed both at spacer and repeat levels. Major distinctive features were identified according to the phylogenetic lineages previously defined by multilocus sequence typing, especially for the sequence type (ST) 17, which is considered hypervirulent. Among other idiosyncrasies, ST-17 shows a significantly lower number of spacers in comparison with other lineages. This characteristic could reflect the peculiar virulence or colonization specificities of this lineage.
Collapse
Affiliation(s)
- Clément Lier
- UMR1282 Infectiologie et Santé Publique, Bactéries et Risque Materno-Foetal, Université de Tours, Tours France ; INRA, UMR1282 Infectiologie et Santé Publique, Nouzilly France ; Service de Bactériologie-Virologie, Hôpital Bretonneau - Centre Hospitalier Régional et Universitaire de Tours, Tours France
| | - Elodie Baticle
- Service de Bactériologie-Virologie, Hôpital Bretonneau - Centre Hospitalier Régional et Universitaire de Tours, Tours France
| | | | - Eve Haguenoer
- UMR1282 Infectiologie et Santé Publique, Bactéries et Risque Materno-Foetal, Université de Tours, Tours France ; INRA, UMR1282 Infectiologie et Santé Publique, Nouzilly France
| | - Anne-Sophie Valentin
- UMR1282 Infectiologie et Santé Publique, Bactéries et Risque Materno-Foetal, Université de Tours, Tours France ; INRA, UMR1282 Infectiologie et Santé Publique, Nouzilly France ; Service de Bactériologie-Virologie, Hôpital Bretonneau - Centre Hospitalier Régional et Universitaire de Tours, Tours France
| | - Philippe Glaser
- Unité de Biologie des Bactéries Pathogènes à Gram Positif, Institut Pasteur, Paris France ; CNRS UMR 3525, Paris France
| | - Laurent Mereghetti
- UMR1282 Infectiologie et Santé Publique, Bactéries et Risque Materno-Foetal, Université de Tours, Tours France ; INRA, UMR1282 Infectiologie et Santé Publique, Nouzilly France ; Service de Bactériologie-Virologie, Hôpital Bretonneau - Centre Hospitalier Régional et Universitaire de Tours, Tours France
| | - Philippe Lanotte
- UMR1282 Infectiologie et Santé Publique, Bactéries et Risque Materno-Foetal, Université de Tours, Tours France ; INRA, UMR1282 Infectiologie et Santé Publique, Nouzilly France ; Service de Bactériologie-Virologie, Hôpital Bretonneau - Centre Hospitalier Régional et Universitaire de Tours, Tours France
| |
Collapse
|
7
|
Guigon A, Lier C, Buret J, Guinard J, Poisson DM, Hennequin C. Endocardite à Penicillium marneffei : suivi de deux marqueurs sérologiques. J Mycol Med 2014. [DOI: 10.1016/j.mycmed.2014.01.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Desoubeaux G, Maakaroun-Vermesse Z, Lier C, Bailly É, Morio F, Labarthe F, Bernard L, Chandenier J. Successful treatment with fumagillin of the first pediatric case of digestive microsporidiosis in a liver-kidney transplant. Transpl Infect Dis 2013; 15:E250-9. [DOI: 10.1111/tid.12158] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 08/13/2013] [Accepted: 09/17/2013] [Indexed: 11/30/2022]
Affiliation(s)
- G. Desoubeaux
- Service de Parasitologie - Mycologie - Médecine tropicale; CHU de Tours; Tours France
- Faculté de Médecine; Université François Rabelais; CEPR UMR INSERM U1100/E.A. 6305; Tours France
| | - Z. Maakaroun-Vermesse
- Service de Médecine Interne et Maladies Infectieuses; CHU de Tours; Tours France
- Service de Médecine Pédiatrique; CHU de Tours; Tours France
| | - C. Lier
- Service de Parasitologie - Mycologie - Médecine tropicale; CHU de Tours; Tours France
| | - É. Bailly
- Service de Parasitologie - Mycologie - Médecine tropicale; CHU de Tours; Tours France
| | - F. Morio
- Laboratoire de Parasitologie et Mycologie Médicale; CHU de Nantes; Nantes France
- IICiMed/E.A. 1155; Université de Nantes; Nantes France
| | - F. Labarthe
- Service de Médecine Pédiatrique; CHU de Tours; Tours France
- Faculté de Médecine; Université François Rabelais; N2C INSERM U1069; Tours France
| | - L. Bernard
- Faculté de Médecine; Université François Rabelais; CEPR UMR INSERM U1100/E.A. 6305; Tours France
- Service de Médecine Interne et Maladies Infectieuses; CHU de Tours; Tours France
| | - J. Chandenier
- Service de Parasitologie - Mycologie - Médecine tropicale; CHU de Tours; Tours France
- Faculté de Médecine; Université François Rabelais; CEPR UMR INSERM U1100/E.A. 6305; Tours France
| |
Collapse
|